Identifying Alzheimer’s Disease biomarker proteins with whole blood tests
A University of Manchester spin-out pharmaceutical company, PharmaKure, has reported successful study results for the quantification of Alzheimer’s Disease biomarker proteins with a whole blood test.
Pharmaceutical company PharmaKure has announced a novel whole blood test that can quantify blood-based biomarkers for Alzheimer’s Disease with successful study results. These biomarkers can be identified to provide early warning of cognitive decline in patients with Alzheimer’s Disease.
By testing whole blood samples, the study accessed a number of biomarkers for the stratification of Alzheimer’s subjects previously tested for amyloid deposits. This was done using brain PET imaging or cerebrospinal fluid (CSF). The levels of these biomarker proteins were measured in the blood of these patients at the early stages of the disease. The proteins included amyloid-β, α-synuclein, and Tau, key biomarkers all associated with Alzheimer’s Disease pathology. Machine learning technology was used to combine blood biomarker and patient data to develop predictive tools.
It was demonstrated that whole blood can be used to identify those at high risk of developing Alzheimer’s Disease. The machine learning software also allowed for the identification of which biomarkers are most useful to predict high Alzheimer’s Disease risk. The whole blood test is now PharmaKure’s proprietary ALZmetrixTM blood test.
Professor Andrew Doig, Head of R&D at PharmaKure, comments: “We are particularly pleased to find that our ALZmetrix blood test can differentiate between patient groups that are amyloid positive or amyloid negative with 97% accuracy to predict those at highest risk of Alzheimer’s Disease. Age, APOE4 and pTau are the most useful features in the prediction. We have also shown that blood can track disease progression, primarily using levels of Tau and pTau.”
CEO at PharmaKure Limited Dr Farid Khan adds: “These results represent an important step in developing whole blood tests to address a major unmet need for an alternative to PET and CSF scans. This study has demonstrated how to get early warning signs of cognitive decline using whole blood. We will be using the exciting data to expand our ALZmetrix test to additional patients and new biomarkers.”
Additionally, a key advantage of testing whole blood samples is the ability to develop a screening system to detect Alzheimer’s before major memory problems become apparent. Early treatment is paramount to providing better health outcomes, improving patients’ quality of life, and lowering healthcare and system costs. “Using the ALZmetrix test for Alzheimer’s could provide a low cost, easily accessible test for stratifying patients for clinical studies, as an alternative to expensive brain scans or other plasma-based tests,” Dr Bob Smith, Clinical Director at PharmaKure, states.
Related News
-
News Pharmapack Awards 2024 Patient-Centric Design Award Winner – Dr Ferrer BioPharma
The 2024 Pharmapack Awards celebrated the best in innovation and design for the pharmaceutical packaging and drug delivery industry on January 24, 2024. -
News Women in Pharma: Minding the Gap at Pharmapack 2024
2024 marks the first year Pharmapack will host a Diversity track dedicated to bridging the gap within the pharmaceutical packaging and drug delivery sector. The track includes a panel discussion on 'Enabling Diversity in the Workplace,' focused... -
News Pharmapack Awards 2024 - Celebrating Packaging and Drug Delivery Innovation
The 2024 Pharmapack Innovation Awards ceremony celebrated the best in pharmaceutical packaging and drug delivery innovation at all levels. The awards were held on January 24, 2024 at the Paris Expo Porte de Versailles. -
News 2024 Pharma Industry Trends Outlook: Collaboration, Market Maturity, and Digital Futures
The annual CPHI Online 2024 Pharma Trends Outlook, in partnership with Arvato Systems, identifies 12 key industry trends shaping the life sciences industry in the coming year. -
News New Novo Nordisk AI hub for drug discovery to open in London, UK
Danish pharmaceutical giant Novo Nordisk will be opening an AI-based research facility in the heart of London to advance drug discovery operations. -
News BioNTech to begin mRNA vaccine manufacturing in Rwanda by 2025
German biotechnology company BioNTech has stated their intentions to begin production at their mRNA vaccine factory in Rwanda by 2025, which will mark the first foreign mRNA vaccine manufacturing site on the continent of Africa. -
News Women in Pharma: Looking back on 2023 and moving forward to 2024
In this monthly series, we interview women from across the pharmaceutical industry and supply chain to discuss the importance of gender diversity in healthcare, the workplace, and beyond. -
News CPHI Barcelona 2023: Partnering for Success – Managing Outsourcing Relationships to Optimise Manufacturing Operations
During CPHI Barcelona 2023, insightful content sessions offered attendees the chance to explore trending topics with expert speakers and panellists. Here, we summarise what the pharma industry and supply chain are talking about the most.
Position your company at the heart of the global Pharma industry with a CPHI Online membership
-
Your products and solutions visible to thousands of visitors within the largest Pharma marketplace
-
Generate high-quality, engaged leads for your business, all year round
-
Promote your business as the industry’s thought-leader by hosting your reports, brochures and videos within your profile
-
Your company’s profile boosted at all participating CPHI events
-
An easy-to-use platform with a detailed dashboard showing your leads and performance